Cencora (COR) reported fourth quarter net income attributable to Cencora of $519.4 million compared to a loss of $339.7 million, prior year. Profit per share was $2.71 for the fourth quarter, compared to a loss of $1.75 in the prior year quarter. Adjusted EPS increased 21.4 percent to $4.66. Fourth quarter revenue increased 5.5 percent to $88.4 billion.
For fiscal 2027, the company estimates adjusted EPS to be in the range of $19.40 to $19.75, reflecting growth of 8 percent to 10 percent. Revenue growth is projected to be 3% to 5%.
Also, Cencora announced that it is realigning its corporate and reporting structure. Cencora is bringing together its specialty businesses under one leader, Richard Tremonte. These businesses will be reported under the Specialty Pharmaceutical and Provider Services segment. Cencora's remaining U.S. businesses and its smaller European wholesale pharmaceutical distribution business will be organized under the Pharmaceutical Distribution and Services segment.
On November 3, 2026, the company declared a quarterly dividend of $0.66 per common share, a 10 percent increase in its quarterly dividend rate. The quarterly dividend is payable November 30, 2026, to s...